RU2015106714A - Прогнозирование ответа на лечение ингибитором jak/stat - Google Patents
Прогнозирование ответа на лечение ингибитором jak/stat Download PDFInfo
- Publication number
- RU2015106714A RU2015106714A RU2015106714A RU2015106714A RU2015106714A RU 2015106714 A RU2015106714 A RU 2015106714A RU 2015106714 A RU2015106714 A RU 2015106714A RU 2015106714 A RU2015106714 A RU 2015106714A RU 2015106714 A RU2015106714 A RU 2015106714A
- Authority
- RU
- Russia
- Prior art keywords
- biomarkers
- jak
- level
- stat inhibitor
- cish
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract 26
- 238000000034 method Methods 0.000 claims abstract 42
- 239000000090 biomarker Substances 0.000 claims abstract 36
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims abstract 22
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims abstract 22
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims abstract 22
- 102100032218 Cytokine-inducible SH2-containing protein Human genes 0.000 claims abstract 16
- 101000943420 Homo sapiens Cytokine-inducible SH2-containing protein Proteins 0.000 claims abstract 16
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims abstract 15
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims abstract 15
- 102100027641 DNA-binding protein inhibitor ID-1 Human genes 0.000 claims abstract 13
- 101001081590 Homo sapiens DNA-binding protein inhibitor ID-1 Proteins 0.000 claims abstract 13
- 108020004999 messenger RNA Proteins 0.000 claims abstract 12
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims abstract 10
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims abstract 10
- 201000011510 cancer Diseases 0.000 claims abstract 10
- 230000002489 hematologic effect Effects 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000012472 biological sample Substances 0.000 claims abstract 5
- 239000000523 sample Substances 0.000 claims abstract 5
- -1 7H-pyrrolo [2,3-d] pyrimidin-4-yl Chemical group 0.000 claims abstract 4
- 206010025323 Lymphomas Diseases 0.000 claims abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract 2
- 208000032839 leukemia Diseases 0.000 claims abstract 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims abstract 2
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims 10
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims 10
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 claims 10
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical group C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 5
- 102100023226 Early growth response protein 1 Human genes 0.000 claims 4
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 claims 4
- 230000005540 biological transmission Effects 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 abstract 1
- 239000010802 sludge Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261676484P | 2012-07-27 | 2012-07-27 | |
| US61/676,484 | 2012-07-27 | ||
| US201361769271P | 2013-02-26 | 2013-02-26 | |
| US61/769,271 | 2013-02-26 | ||
| US201361829327P | 2013-05-31 | 2013-05-31 | |
| US61/829,327 | 2013-05-31 | ||
| PCT/US2013/051824 WO2014018632A1 (en) | 2012-07-27 | 2013-07-24 | Prediction of treatment response to jak/stat inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015106714A true RU2015106714A (ru) | 2016-09-20 |
Family
ID=48906529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015106714A RU2015106714A (ru) | 2012-07-27 | 2013-07-24 | Прогнозирование ответа на лечение ингибитором jak/stat |
Country Status (18)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| UY36032A (es) | 2014-03-14 | 2015-10-30 | Novartis Ag | Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas |
| CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| CR20170410A (es) | 2015-03-10 | 2017-11-08 | Aduro Biotech Inc | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen interferon" |
| US11098077B2 (en) | 2016-07-05 | 2021-08-24 | Chinook Therapeutics, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| CN106544414A (zh) * | 2016-10-09 | 2017-03-29 | 广州泰诺迪生物科技有限公司 | 一种检测肺癌脑转移样本中stat3和lck的方法 |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| CN107137701B (zh) * | 2017-05-07 | 2020-07-14 | 山东兴瑞生物科技有限公司 | 一种提高dc疫苗抗肝癌效果的基因靶标、抑制剂和dc肿瘤疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US20060194275A1 (en) * | 2001-04-13 | 2006-08-31 | Incyte Corporation | Transporter and ion channels |
| WO2010048123A2 (en) * | 2008-10-20 | 2010-04-29 | Eckhardt S Gail | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| NZ597140A (en) * | 2009-06-05 | 2014-01-31 | Cephalon Inc | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| BR112013013684A2 (pt) * | 2010-12-03 | 2016-09-06 | Ym Biosciences Australia Pty | tratamento das condiçóes mediadas por jak-2 |
-
2013
- 2013-07-24 BR BR112015001521A patent/BR112015001521A2/pt not_active IP Right Cessation
- 2013-07-24 EP EP13742819.9A patent/EP2877596A1/en not_active Withdrawn
- 2013-07-24 AU AU2013295855A patent/AU2013295855A1/en not_active Abandoned
- 2013-07-24 JP JP2015524417A patent/JP2015526074A/ja active Pending
- 2013-07-24 SG SG11201500261VA patent/SG11201500261VA/en unknown
- 2013-07-24 RU RU2015106714A patent/RU2015106714A/ru not_active Application Discontinuation
- 2013-07-24 HK HK15105427.5A patent/HK1205198A1/xx unknown
- 2013-07-24 CN CN201380040005.0A patent/CN104508149A/zh active Pending
- 2013-07-24 US US14/417,632 patent/US20150299796A1/en not_active Abandoned
- 2013-07-24 WO PCT/US2013/051824 patent/WO2014018632A1/en not_active Ceased
- 2013-07-24 CA CA2880198A patent/CA2880198A1/en not_active Abandoned
- 2013-07-24 KR KR20157004583A patent/KR20150038241A/ko not_active Withdrawn
- 2013-07-24 MX MX2015001269A patent/MX2015001269A/es unknown
- 2013-07-26 TW TW102126993A patent/TW201409030A/zh unknown
-
2015
- 2015-01-16 TN TNP2015000019A patent/TN2015000019A1/fr unknown
- 2015-01-22 IL IL236897A patent/IL236897A0/en unknown
- 2015-01-26 CL CL2015000192A patent/CL2015000192A1/es unknown
- 2015-01-26 PH PH12015500169A patent/PH12015500169A1/en unknown
-
2017
- 2017-07-14 AU AU2017204894A patent/AU2017204894A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015001521A2 (pt) | 2017-11-07 |
| TW201409030A (zh) | 2014-03-01 |
| IL236897A0 (en) | 2015-03-31 |
| AU2013295855A1 (en) | 2015-02-12 |
| US20150299796A1 (en) | 2015-10-22 |
| KR20150038241A (ko) | 2015-04-08 |
| EP2877596A1 (en) | 2015-06-03 |
| WO2014018632A1 (en) | 2014-01-30 |
| AU2017204894A1 (en) | 2017-08-03 |
| HK1205198A1 (en) | 2015-12-11 |
| CL2015000192A1 (es) | 2015-06-26 |
| MX2015001269A (es) | 2015-05-08 |
| JP2015526074A (ja) | 2015-09-10 |
| SG11201500261VA (en) | 2015-02-27 |
| CA2880198A1 (en) | 2014-01-30 |
| TN2015000019A1 (en) | 2016-06-29 |
| CN104508149A (zh) | 2015-04-08 |
| PH12015500169A1 (en) | 2015-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015106714A (ru) | Прогнозирование ответа на лечение ингибитором jak/stat | |
| Daver et al. | FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia | |
| Shah et al. | Prognostic significance of molecular markers in oral squamous cell carcinoma: a multivariate analysis | |
| Mahon et al. | Deep molecular response in chronic myeloid leukemia: the new goal of therapy? | |
| Ozeki et al. | Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia | |
| Antonescu et al. | ZFP36‐FOSB fusion defines a subset of epithelioid hemangioma with atypical features | |
| Moreau et al. | Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol | |
| Hilberg et al. | Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis | |
| Taschner-Mandl et al. | Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence | |
| Sadozai et al. | Distinct stromal and immune features collectively contribute to long-term survival in pancreatic cancer | |
| Park et al. | Active surveillance for metastatic or recurrent renal cell carcinoma | |
| JP2015526074A5 (cg-RX-API-DMAC7.html) | ||
| Su et al. | Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation | |
| Hayes et al. | The next steps in next-gen sequencing of cancer genomes | |
| Kim et al. | The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients | |
| Nogueira-Rodrigues et al. | Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer | |
| Lu et al. | Endothelial cell-specific molecule 1 drives cervical cancer progression | |
| Liu et al. | Activation of mammalian target of rapamycin pathway confers adverse outcome in nonsmall cell lung carcinoma | |
| Twardowski et al. | Papillary renal cell carcinoma: current progress and future directions | |
| Magro et al. | Atypical lymphocytic lobular panniculitis: a clonal subcutaneous T‐cell dyscrasia | |
| Sasse et al. | Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group | |
| Cheng et al. | Emerging drugs for squamous cell lung cancer | |
| Kempf et al. | 10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient | |
| Eliades et al. | A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors | |
| Semrad et al. | Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor therapy in patients with renal cell carcinoma who have progressed on bevacizumab, Pazopanib, sorafenib, or sunitinib–results of NCI/CTEP protocol 9048 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180816 |